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doi:10.1016/j.jtcvs.2003.11.050TObjective: The clinical behavior of penetrating atherosclerotic ulcers of the aorta is
controversial. We reviewed our experience with this entity over a 25-year interval.
Methods: Cases were identified using the Department of Radiology database search-
ing for the diagnoses of aortic dissection, intramural hematoma, or penetrating ulcer
between 1977 and 2002. Available imaging studies were reviewed by a vascular
radiologist to confirm the diagnosis of penetrating ulcer and perform serial mea-
surements.
Results: One hundred five patients with penetrating atherosclerotic ulcers of the
descending thoracic aorta or arch with (n  85) or without (n  20) associated
intramural hematoma were confirmed. Two patients with ulcers in the ascending
aorta were excluded. There were 73 men and 32 women with a mean age of 72 
9 years. Comorbidities included hypertension in 97 (92%), tobacco use in 81 (77%),
and coronary artery disease in 48 (46%). Of nonoperated patients with follow-up
studies, the mean thickness of the intramural hematoma decreased at 1 month in
89% and completely resolved at 1 year in 85%. There were 3 deaths (4%) within 30
days among 76 patients treated medically and 6 deaths (21%) among 29 patients
treated surgically (P  .05). Failure of medical therapy defined as surgery or death
was predicted by rupture at presentation (odds ratio  20.6) and era of treatment
(before 1990, odds ratio 9.9) but not aortic diameter, ulcer size, or extent of
hematoma.
Conclusion: Although careful follow-up is necessary, many penetrating atheroscle-
rotic ulcers of the thoracic aorta can be managed nonoperatively in the acute setting.
In recent years subtypes of acute aortic pathology including penetratingatherosclerotic ulcer (PAU) and intramural hematoma (IMH) have beenrecognized in addition to classic aortic dissection as etiologies of “acuteaortic syndromes.”1 Although these conditions may simply represent vari-ants of dissection,2,3 data are accumulating to suggest there may be differ-ences in the clinical behavior of these entities.4-6 Accordingly, despite
general agreement regarding the natural history of classic aortic dissection and
hence the indications for surgical intervention in that condition, debate persists
regarding PAU and IMH.
When attention was drawn to PAU by Stanson and associates7 in 1986, this entity
was thought to have a particularly malignant behavior warranting an aggressive
surgical posture. Shortly thereafter, however, Hussain and colleagues8 presented
convincing evidence that nonoperative management was successful in many cases.
More recently others9 have supported the original view with data suggesting that
PAU is even more malevolent than classic dissection.
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IMH. Initial reports supported surgical therapy of IMH
involving the ascending aorta (type A) and medical therapy
of those confined to the descending aorta (type B).10 More
recently expectant therapy of type A IMH has been advo-
cated by some4 while other investigators counter that both
IMH and PAU are “virulent vascular lesions” for which
prompt surgical intervention is indicated.11 It has also been
suggested that the presence of PAU in combination with
IMH is particularly ominous.12
We have had particular interest in PAU at our center for
some time.7 Accordingly, we have reviewed our clinical
experience over the past 25 years to examine the behavior of
PAU with or without associated IMH.
Materials and Methods
The database of the Department of Diagnostic Radiology was
searched for cases with the diagnosis of aortic dissection, IMH, or
PAU between July 1977 and August 2002. Of 1064 cases so
identified, reports were reviewed and clear cases of aortic dissec-
tion without evidence of hematoma or penetrating ulcer were
eliminated. Of the remaining 163 patients, available aortograms
and computerized tomographic (CT) scans were reviewed by a
cardiovascular radiologist (A.W.S.) blinded to clinical course. Of
107 patients found to have penetrating ulcers of the thoracic aorta,
2 had ulcers in the ascending aorta and were excluded from this
analysis. In 16 cases intramural hematoma was identified at an-
giography by examining the aortic profile against the background
lung tissue on the left side of the aorta with a wall thickness greater
than 5 mm considered diagnostic.7 The diagnostic criteria of IMH
by CT scanning included asymmetric wall thickening greater that
3 mm as determined by medial displacement of intimal calcifica-
tion or the presence of high density, indicating hematoma in the
acute setting. The medical records of confirmed cases of PAU with
or without IMH were reviewed for clinical presentation and in-
hospital course. All subsequent imaging studies were examined for
evolution of the lesion. Late follow-up was obtained by chart
review, search of the social security death index, and telephone
Figure 1. Dimensions of penetrating atherosclerotic ulcers. Ulcer
dimensions were determined as shown from all available com-
puterized tomographic scans.interview. Death certificates were obtained whenever possible (16
1394 The Journal of Thoracic and Cardiovascular Surgery ● Macases) to determine cause of death. Follow-up information was
available in 90% of patients within the last 5 years and 88% of
patients within the last 3 years.
The ulcer location was recorded as involving the aortic arch or
the proximal, middle, or distal third of the descending thoracic
aorta. Ulcer dimensions were measured according to maximum
depth from the lumen into the aortic wall, maximum width at entry
site from the lumen, and maximum length of the intramural com-
ponent of the ulcer itself (Figure 1). Intramural hematoma confined
to 2 or fewer of these segments was defined as localized, whereas
those involving more than 2 segments were defined as extensive.
Data are expressed as mean  standard deviation or as propor-
tions. Univariate analysis was performed on all clinical and radio-
logical measurements with 2 test used for categorical variables
and unpaired Student t test used for continuous variables. Multi-
variate logistic regression analysis was carried out using variables
significant by univariate analysis and those suspected on clinical
grounds. Survival was estimated and compared by Kaplan-Meier
analysis with log-rank test.
Results
The study group was characterized by advanced age, with
hypertension almost universal and tobacco abuse common
(Table 1). Most patients were symptomatic on presentation,
typically with back pain. Asymptomatic ulcers were iden-
tified during the course of evaluation of an abnormal chest
radiograph in 11, evaluation of other aneurysmal disease in
6, and incidental to the evaluation of other intrathoracic (n
 6) or extrathoracic (n  2) pathology.
Approximately equal proportions of the medical and
surgical groups were symptomatic upon presentation. Aor-
tic pathology was similar in both medically and surgically
treated patients (Table 2). Most ulcers were associated with
an IMH, slightly over half of which were localized in extent.
Patients going to surgery tended to have only slightly larger
aortic diameter than those treated medically.
Over the course of the study interval almost one-third of
patients underwent surgery, although this evolved over time
with 19 of 31 (61%) treated surgically between 1977 and
1990 and 10 of 74 (14%) treated surgically since 1991.
Cited indications for surgery included known or suspected
rupture in 9 patients, refractory pain in 5, and increasing
aortic size in 4. Three additional patients underwent surgery
because involvement of the arch was judged by the treating
physicians at the time to be an indication for surgery and
another 3 early in the experience when presence of an ulcer
was felt to be an indication. One patient underwent surgery
because of acute paraplegia, the only instance of branch
vessel occlusion recognized, and 1 for mycotic involvement
of the ulcer. Of 73 patients who survived the initial nonop-
erative management, 6 underwent late surgery for enlarging
aneurysm and 2 for ruptured abdominal aortic aneurysm.
Early mortality was 4% in the medically treated patients
and 21% for the surgical group (Table 3). Surgical mortality
increased in the latter part of the series (4 of 10 between
y 2004
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surgery with only those failing medical therapy proceeding
to operation. Late survival is depicted in Figure 2 with a
median follow-up interval of 45.6 months (range 1-189)
among medically treated patients and 29.0 months (range
1-187) for surgical patients. Causes of late death were
known to be related to the aorta in 3 surgical patients and 5
medical patients. There were 4 deaths due to unknown cause
in the surgical group and 11 in the medical group. If these
deaths are attributed to the aorta, the incidence of late death
due to aortic disease in the surgical group would be 7 of 23
or 30% as compared with 15 of 73 or 21% in the medical
group.
A comparison of the aortic pathology in symptomatic
and asymptomatic patients is presented in Table 4. Pleural
effusion, extensive IMH, and rupture were more common
among symptomatic patients possibly evidencing “active”
TABLE 1. Patient profiles
Variables
Medical
(n  76)
Age (y) 72 9
Gender (M:F) 51:25
Comorbidities
Hypertension 70 (92%)
Tobacco use 58 (76%)
COPD 19 (25%)
CAD 35 (46%)
Renal dysfunction 16 (21%)
AAA 46 (61%)
Symptomatic 56 (74%)
Pleural effusion 21 (28%)
Rupture 2 (3%)
COPD, Chronic obstructive pulmonary disease; CAD, coronary artery disea
defined as serum creatinine level greater than 1.5 mg/dL.
TABLE 2. Characteristics of the aortic pathology
Variables
Medical
(n  76)
Location of PAU
Arch 8 (11%)
Descending 71 (93%)
Multiple 9 (12%)
Maximum aortic diameter (mm) 42.4 7.7
Presence of IMH 59 (78%)
Maximum thickness of IMH (mm) 9.9 4.4
Location of IMH*
Ascending 4 (7%)
Arch 14 (24%)
Descending 57 (97%)
Localized IMH* 35 (59%)
PAU, Penetrating atherosclerotic ulcer; IMH, intramural hematoma.
*Of the patients with IMH.disease. Ulcer dimensions were greater among asymptom-
The Journal of Thoracicatic than symptomatic patients, perhaps reflecting a more
TABLE 3. Causes of early (30-d) and late mortality
Surgical Medical
Early (n  6/29, 20.7%) Early (n  3/76, 3.9%)
Intraoperative cardiac
arrest (2)
Rupture (patient refused
surgery) (1)
Stroke (2) Rupture of hepatic artery
aneurysm (1)
Multiorgan failure (1) Sepsis after other surgery (1)
Bleeding (1)
Late (n  18/23, 78%) Late (n  30/73, 42%)
Aorta-related (3) Aorta-related (5)
Other cardiovascular (7) Other cardiovascular (9)
Noncardiovascular (4) Noncardiovascular (5)
Unknown (4) Unknown (11)
P  .05, surgical vs medical.
urgical
 29) P value
Total
(n  105)
 7 NS 72 9
:7 NS 73:32
(93%) NS 97 (92%)
(79%) NS 81 (77%)
(219%) NS 25 (24%)
(45%) NS 48 (46%)
(21%) NS 22 (21%)
(62%) NS 64 (61%)
(79%) NS 79 (75%)
(38%) NS 32 (30%)
(24%) .001 9 (9%)
AA, abdominal aortic aneurysm; NS, not significant. Renal dysfunction is
Surgical
(n  29) P value
Total
(n  105)
1 (3%) NS 9 (11%)
28 (97%) NS 99 (94%)
2 (7%) NS 11 (10%)
47.2 8.1 .09 43.4 7.9
26 (90%) NS 85 (81%)
9.2 2.5 NS 9.7 4.0
1 (4%) NS 5 (6%)
3 (12%) NS 17 (20%)
26 (100%) NS 83 (98%)
14 (54%) NS 49 (58%)S
(n
72
22
27
23
6
13
6
18
23
11
7
se; Achronic process, although this is speculative. Of particular
and Cardiovascular Surgery ● Volume 127, Number 5 1395
significant.
Surgery for Acquired Cardiovascular Disease Cho et al
1396 The Journal of Thoracic and Cardiovascular Surgery ● Ma
A
CDnote, the rate of surgical intervention was similar among
symptomatic and asymptomatic patients, as was the 30-day
mortality. Late outcome of symptomatic and asymptomatic
patients was remarkably similar as well, as shown in Figure
2, B.
The fate of the intramural hematoma is depicted in Fig-
ure 3. Of 58 medical patients, serial CT imaging studies
permitting quantitative comparison of the IMH were avail-
able in 40 (70%). Among these, for scans taken within 30
days of diagnosis, slightly over one-third of the hematomas
demonstrated increase in size and a somewhat larger per-
centage demonstrated stability. For those scans obtained at
approximately 1 month, over one-third demonstrated reso-
lution of the IMH and 10% stability with the remainder
having demonstrated a decrease. By 1 year the vast majority
of intramural hematomas had resolved.
A significant number of patients demonstrated progres-
sion of their ulcer to saccular aneurysm in follow-up. We
distinguish giant ulcer from saccular aneurysm on the basis
of the presence of overhanging edges and shelflike borders,
with the adjacent aortic lumen characterizing the former and
the latter having a seamless transition from sac to adjacent
aortic lumen. Among 54 PAU patients with serial scans, 26
developed an asymmetrical aneurysm. Of these, 5 under-
went late surgery without mortality. The remainder have not
reached size criteria for repair or the patients have declined
operation.
In an effort to evaluate the validity of a treatment algo-
rithm beginning with medical stabilization, we analyzed the
study group by defining failure of medical therapy as ulcer-
related death or surgical intervention. Such an approach is
inherently limited as not all surgical patients were true
medical failures given the aggressive approach undertaken
in the early years. Simple comparison of the outcome of
medical and surgical groups, however, is more gravely
Figure 3. Fate of intramural hematomas among patients with
serial computerized tomographic studies.TABLE 4. Comparison of symptomatic versus asymptom-
atic cases
Variables
Symptomatic
(n  79)
Asymptomatic
(n  26) P value
Arch ulcer 4 (5%) 5 (19%) .03
Pleural effusion 29 (37%) 3 (12%) .02
AAA 42 (53%) 22 (85%) .01
Extensive IMH 32 (54%) 4 (15%) NS
Rupture 8 (10%) 1 (4%) NS
Aortic diameter (mm) 42.7 8.0 44.9 7.8 NS
Thickness of IMH (mm) 9.2 3.6 11.8 5.3 NS
Dimension of ulcer
Depth (mm) 10.0 8.2 12.9 6.9 .01
Width (mm) 13.9 13.8 18.5 10.9 .02
Length (mm) 15.7 17.5 19.4 13.0 .05
Surgery 23 (29%) 6 (23%) NS
30-d mortality 6 (8%) 3 (12%) NS
IMH, Intramural hematoma; AAA, abdominal aortic aneurysm; NS, notFigure 2. A, Actuarial survival of medically (median follow-up
45.6 months, range 1-187) and surgically (median follow-up 29.0
months, range 1-187) treated patients (median follow-up). P  .25
by log-rank test. B, Actuarial survival of patients presenting with
symptomatic (median follow-up 43.6 months, range 1-187) versus
asymptomatic (median follow-up 48.5 months, range 1-189) ulcers.
P  .15 by log-rank test.flawed by selection bias with the most ill patients typically
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rupture on admission and diagnosis before 1990 predicted
surgery or death due to the aorta. Maximum aortic diameter,
ulcer dimensions, symptomatic status, and pleural effusion
did not predict failure of medical therapy. Of note, however,
aortic diameter was only available in 57% of patients as a
number of these diagnoses were made on the basis of
angiograms or early CT scans that lacked appropriate scales.
When aortic diameter was incorporated within a multivari-
ate model, only rupture was a significant predictor. When
aortic diameter was removed from analysis, rupture and
surgery before 1990 were significant predictors.
In an effort to control for referral bias, we analyzed the
subgroup of patients residing within 100 miles of our insti-
tution. Within that radius, 14 other hospitals perform car-
diovascular surgery, 10 of which are in the Twin Cities of
Minneapolis and St Paul. Few patients are referred from
Minneapolis-St Paul given tertiary care centers in that com-
munity; however, apart from that population center it is
likely that our experience represents a significant percentage
of the individuals diagnosed with this entity in our region
with little selection bias. As shown in Table 6, the regional
subgroup was similar to the whole group apart from the
lower frequency of asymptomatic status. One might antici-
pate a higher incidence of incidentally identified ulcers
among patients traveling from a distance to undergo diag-
nostic evaluation of other conditions. There was, however,
no significant difference in rupture, distribution of ulcers,
ulcer dimensions, incidence of surgery, or early mortality.
Discussion
The results of this study indicate that a substantial number
TABLE 5. Predictor for failure of medical therapy (early su
Univariate analysis
Variables
Success
(n  75)
Failure
(n  30)
Female 25 (33%) 7 (23%)
Age 72 9 72 7
Symptomatic 55 (73%) 24 (80%)
AAA 46 (61%) 18 (60%)
Pleural effusion 21 (28%) 11 (37%)
Rupture 1 (1%) 8 (27%)
Arch ulcer 8 (11%) 1 (3%)
Max aorta (mm) 42.4 7.7 47.2 8.1
Ulcer depth (mm) 10.5 8.2 11.1 7.4
Ulcer width (mm) 14.9 14.3 15.1 10.0
Ulcer length (mm) 14.9 14.6 21.0 20.7
Time at diagnosis (1990) 12 (16%) 19 (63%)
AAA, Abdominal aortic aneurysm; Max aorta, maximum aortic diameter. W
were significant predictors for adverse clinical outcomes.
*Aortic diameter was only available in 57% of patients as a number of thes
for measurement.of patients with PAU can be treated nonoperatively in the
The Journal of Thoracicacute setting. Given the high frequency of comorbid condi-
tions in these elderly patients, an expectant approach is
reasonable. The majority of IMH when managed medically
appear to resolve with time, and the risk of acute death
during the index hospitalization among medically treated
patients appears low. This is not to say that this condition
can be treated casually. There is risk of late development of
a saccular aneurysm, and a significant number of patients
require early or late operation. Approximately one-third of
individuals in our study underwent early or late operation,
although this rate is likely inflated somewhat by our aggres-
sive approach to operation for this entity early in our expe-
rience. Given the retrospective nature of the data set, one
cannot predict the outcome had all patients been treated
TABLE 6. Comparison of regional (within 100 miles) and
total cases
Variables
Regional
(n  56)
Total
(n  105)
Symptomatic 50 (89%) 79 (75%)
Pleural effusion 19 (34%) 32 (30%)
Arch ulcers 3 (5%) 9 (9%)
Rupture 7 (13%) 9 (9%)
Surgery 14 (25%) 29 (28%)
Maximum aortic diameter
(mm)
41.6 7.3 43.4 8.0
Ulcer dimension
Depth (mm) 8.3 5.7 10.7 8.0
Width (mm) 11.2 6.7 15.0 13.3
Length (mm) 13.8 15.5 16.5 16.6
Mortality 3 (5%) 9 (9%)
y or death)
Multivariate analysis
value Variables P value
Odds
ratio
NS Rupture .01 20.45
NS Time of diagnosis (1990) .001 9.90
NS
NS
NS
.01
NS
NS
NS
NS
NS
.001
ortic diameter was removed from analysis, rupture and time at diagnosis
noses were made on the basis of angiograms that lacked available scalesrger
P


hen a
e diagexpectantly. In the last decade, however, in which the op-
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mortality rate among medically treated patients remained
low at 3% and the surgical mortality was 40%.
Late mortality in this patient group was high, as was
surgical mortality. We believe that both reflect the comor-
bidities typically present in the patients in whom PAU are
most often seen. The high rate of late cardiovascular death
due to causes other than aneurysmal disease supports this
hypothesis. Surgical mortality was high, likely for the same
reason, and has in fact increased due to adverse selection as
surgery is reserved for only the most ill patients. Of partic-
ular note, while the late survival data is limited by incom-
plete knowledge of the causes of late death, late survival
curves were of similar shape in both the surgical and med-
ical groups, suggesting that early surgery did not protect
these individuals.
Long-term follow-up of these individuals is important. In
our opinion these patients should be cared for by individuals
with particular interest in the entity. The value of beta-
blockade to improve long-term outcome in patients with
IMH has been convincingly demonstrated.3 At a minimum
these results can be applied to patients with PAU and IMH
and, we believe, likely to those with PAU without IMH as
well. Patients with PAU have previously been shown to be
at ongoing risk of development of late pseudoaneurysm,
rupture, or dissection11,13,14 and accordingly should be
monitored closely by appropriate specialists. The advent of
endovascular stent grafts15-17 offers yet another option in
the management of these complex patients and highlights
the importance of a multidisciplinary approach to their care.
It should also be noted that the use of these devices entails
early and late risks, and their application should be directed
by a sophisticated understanding of the natural history of
these conditions.
We were unable to identify useful predictors of clinical
behavior of the aortic pathology. Only rupture was a pre-
dictor of surgery or death due to the aortic disease. In a
previous analysis restricted to those PAU complicated by
IMH, maximum aortic diameter did reach statistical signif-
icance with a P value of .03 but an odds ratio of only 1.13
(data not shown). In analysis of the entire group including
those PAU without IMH, there was a statistically insignif-
icant trend toward larger aortic diameter in the surgical
group than medical group; however, these data were only
available in 57% of cases. Others, however, have data
suggesting that maximum aortic diameter may be a useful
indicator of clinical behavior.18-20 Curiously, in 1 recent
study, smaller aortic diameter was associated with progres-
sion.3 Our study also did not identify ulcer size as a pre-
dictor of progression as suggested by others.12 In our opin-
ion these conflicting results reflect the limitations of what
remain relatively small data sets. Intriguingly, in our study,
neither the symptomatic status of patients nor the presence
1398 The Journal of Thoracic and Cardiovascular Surgery ● Maof an IMH appeared to be a useful indicator. The number of
ulcers involving the aortic arch was small, and our study did
not identify location of either ulcer or hematoma as predic-
tive of outcome. Similarly the extent of the intramural
hematoma did not predict outcome. The subject clearly
warrants further study.
Our recommendations for clinical management are
somewhat at variance with those of Coady and colleagues9
and Tittle and colleagues.11 Although we agree that this is a
high-risk subset of patients, we advocate a more expectant
approach in their management. This may in part be due to
differences in patient populations, with selection bias favor-
ing referral of the most gravely and acutely ill to a quater-
nary facility in an area of high population density while
more stable patients remain in regional facilities. Although
our institution is a referral center as well, we have a large
regional practice with few competing sites outside of the
Twin Cities performing cardiac surgery. Our data set, there-
fore, may be more representative of the condition as ob-
served in the community. It should be noted as well that
nonoperative management of IMH, particularly involving
the descending thoracic aorta, has been advocated previ-
ously by others10,21,22 and resolution of IMH has also been
reported.19 Recently some authors have even suggested that
IMH involving the ascending aorta might be treated non-
operatively.23 Our data do not address this issue, and we do
not endorse this approach. However, the level of contro-
versy over management of acute aortic syndromes should be
emphasized.
Without question, significant limitations of our study
must be recognized. Although it represents a 25-year expe-
rience and a large number of cases relative to those previ-
ously reported in the literature, numbers are still small,
making statistical analyses difficult. Recently this problem
has been addressed via meta-analysis22; however, this ap-
proach is subject to profound reporting bias. Incomplete
follow-up imaging scans as well as incomplete long-term
clinical follow-up and knowledge of the cause of death are
further limitations our study shares with many others in the
literature. Despite these limitations we feel that these data
support expectant therapy of these difficult lesions, which
most often occur in a complex patient population.
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Discussion
Dr John A. Elefteriades (New Haven, Conn). I would like to
congratulate the authors on a very important contribution to this
topic. Because these are new diseases of the current era of CT,
magnetic resonance imaging, and transesophageal echocardio-
graphic imaging, our understanding of their pathophysiology, nat-
ural behavior, and optimal treatment are incomplete, and this
important paper helps us to understand these entities better.
I have a number of questions for Dr Cho. First, I would like to
ask you about definitions. In the text, you indicate that nearly half
of your cases were diagnosed by angiography alone. This reflects
the 25-year time span of your review. How could you make a
diagnosis of intramural hematoma based on an angiogram? Also,
I wonder, why did you exclude ulcers without intramural hema-
The Journal of Thoracictoma from your study group, and if you included them, does the
behavior become more benign or more malignant?
Next, I would like to ask you about the acuity of presentation.
You did not exclude ulcers presenting as incidental findings in
patients who are well without an acute aortic syndrome. What are
the rates of malignant behavior if those patients with only inci-
dental findings are excluded?
And then I would like to ask you about your management
recommendations. In particular, you state that most cases can be
managed nonoperatively in the acute setting, yet one-third of your
patients had serious early complications requiring immediate op-
eration and nearly 20% of the patients died in midterm follow-up.
These data reflect a serious condition with quite a dismal progno-
sis. Do you think we should be cautious in communicating to the
audience any message of benignity regarding the behavior of these
lesions?
And then I would like to ask you a few brief questions about the
general aspects of these conditions that may be interesting to the
audience.
As you can see in that picture there, these lesions look exactly
like duodenal ulcers, and I wonder what your thoughts are about
the etiology of these conditions. We have looked diligently for
pathogens, including Helicobacter, and we have not found them.
An obvious question is, have you ever considered stent grafting for
these lesions?
And finally, I would like to ask you about branch vessel
occlusion. In our experience, these lesions, in contradistinction to
typical aortic dissection, never produce a branch vessel occlusion.
Did you indeed identify any ischemic vascular complications in
your series of patients?
Dr Sundt. Thank you, Dr Elefteriades. There is a symmetry to
this that some may appreciate. A few years ago I had the privilege
of discussing Dr Elefteriades’ series in this forum, and it just goes
to show you that what goes around comes around. So be careful
what you ask people, they may come back and ask you the same
thing. It is a good rule in life, I suppose.
This is an exciting time in the treatment I think of aortic disease
because, thanks to series like those that John has accumulated and
the one I hope that we have contributed to the literature here, we
can actually move from anecdote to evidence. Up to this point, the
majority of literature concerning these entities have really had just
a handful of patients in any particular subgroup.
You asked about definitions, specifically the definition at an-
giography of intramural hematoma. We relied very much on Dr
Stanson, who was our radiologist in this endeavor and was the
individual who originally described this entity in 1986, and Dr Cho
and Dr Stanson spent many hours reviewing each and every one of
these studies. The CT and magnetic resonance criteria were pres-
ence of an ulcer and thickening of the wall greater than 3 mm and
by angiography, and it is a challenge to make this diagnosis by
angiography. Dr Stanson required a thickening of the wall apparent
by angiography of at least 5 mm.
For the question about excluding penetrating ulcers without
intramural hematomas, this is another issue concerning these en-
tities and is reminiscent of Craig Miller’s comment yesterday
about apples and oranges: it sort of depends on whether you are a
lumper or a splitter. How are you going to divide up these entities?
Do intramural hematomas with ulcers behave differently than
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ences in behavior for ulcers with and without hematoma?
We have thought of this particular entity of intramural hema-
toma predominantly as a condition that reflects disease of the media
and of ulcers as a condition that reflects disease of the intima. And I
think that at least as a first pass we ought to try and focus on each of
these entities in the different quadrants defined by these axes of
disease. So that is why we focused on this particular area, although it
does not appear to yield significantly different results if you look at
penetrating ulcers without intramural hematoma. They appear to
behave in a very similar way, at least at first pass.
What about asymptomatic ulcers with hematomas and do they
behave differently, those that were identified incidentally? In fact
it appears that they behave in a very similar way. So at least at this
point with still very small numbers we cannot tease out subgroups
that behave particularly badly or particularly well, which comes to
the issue of recommendations. And I agree with you, I don’t think
the message is that you can forget about them.
These people ought to be followed carefully. They ought to be
followed by individuals with interest in aortic disease, which is to
say that in my opinion they should not be given up to the cardi-
ologists in the cardiac care unit who are really more interested in
acute myocardial infarction than they are in aortic disease.
Someone, whether it is a cardiologist or a surgeon with interest
in aortic disease, ought to follow these patients and that is how we
will get the best long-term results with this.
I agree that it requires judgment, and I think that that is the
take-home lesson to this is that it is not a knee-jerk reflex that they
need to be operated on and it is not a knee-jerk reflex that they can
be treated nonoperatively. We still need to exercise surgical judg-
ment.
With regard to the etiology, I don’t know the etiology of it apart
from this concept that it is a disease of the intima, and I am very
intrigued by your notion that they may be related to having an
infectious etiology.
Stent grafting again relates to what their long-term behavior is.
If in fact they have a relatively benign behavior or if there is a
subgroup that has relatively benign behavior, then I don’t think we
should be deploying stent grafts willy-nilly in all of these aortas.
These are old, fragile patients; they are going to have complica-
tions related to groin cannulation to pass these stent grafts. They
are really not people that you want to touch, if you can help it.
We have not seen branch vessel occlusion, as was your expe-
rience. This does not appear to be a component of this entity.
Dr Irving L. Kron (Charlottesville, Va). Dr Sundt, this is a
wonderful contribution. These are often ancient patients, as you all
know, and you hate to even start an intravenous line on them, let
alone an aortic operation.
My question is specific to the arch. You mentioned there was
no difference in terms of acuteness and what you did. What about
late term? And more importantly, though you didn’t speak of this,
I am sure it is in your review at Mayo Clinic, what about the
hematoma of the ascending aorta? We now consider that a surgical
indication. Can you shed some more light on that? Thank you.
Dr Sundt. To directly answer your question, the reason I think
that location didn’t come out as a predictor is that the numbers of
ulcers and hematomas in the ascending aorta and arch were very
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literature, perhaps 1 of the reasons that people come up with
different recommendations is that as you go from 1 series to
another, there can be a very marked difference in distribution. So
in a series that shows 50% of the ulcers and hematomas to be in the
ascending aorta, it is not surprising to me that they find a natural
history rather than another series that is published that has 2% in
the ascending aorta or in the arch. I think we need to be precise
about those definitions.
I think that all of us at Mayo would agree that we tend to be
very aggressive with ascending aortas. I think that the operative
risk is probably less for a tube graft of the ascending aorta than it
is management of an arch lesion or a descending thoracic aorta.
The arch is difficult because one would think logically that those
would be “bad actors.”
Again, we don’t have enough data to speak of that, but, as you
said, these are often ancient patients with extensive atherosclerotic
disease, and the prospect of an arch replacement in them is not
very appealing. So I don’t know what to say about the arch other
than to use judgment. If one feels that one can do an arch replace-
ment at reasonable risk, that is certainly a reasonable thing to do,
but I don’t think that the mere presence of an ulcer in the arch
mandates immediate surgical intervention.
Dr Lars G. Svensson (Cleveland, Ohio). Dr Sundt, I would like
to congratulate you and your group at Mayo Clinic for bringing to us
this big study with a large series of patients. I should point out that Dr
Shannon Shumacker actually described the entity, although there was
a period when there wasn’t much written about it.
One of the things we noticed in the 1980s and 1990s in treating
these patients medically as type III DeBakey dissections was that
a number of them ruptured. We then did postmortem studies on
them and found that the plane of dissection or the hematoma is
different than the classic dissections and that it is not in the media
but between the media and the adventitia. I think that is why we
see more pleural effusions and why we see perhaps more often
patients rupturing, as some of the data from Yale would also
suggest. So we have adopted a more aggressive approach and we
routinely now stent these patients, and we have had good results.
There are some papers coming out showing good results.
I certainly would encourage you to be more aggressive in
treating them in the acute situation when they present with a
hematoma, and including obviously, as Dr Kron has pointed out,
the patients with ascending and arch hematomas.
As I recall, you do a lot of autopsies at the Mayo Clinic. Did you
look at the plane of dissection in these patients who may have died?
Dr Sundt. We have not tapped those effusions, and in fact, as
far as we could tell from this analysis, the presence of an effusion
didn’t predict behavior either.
Dr Robert Dion (Leiden, The Netherlands). I would like to ask
you, in the presence of pleural effusion, what is your rationale?
Are you going in all the time or are you puncturing to see if it is
blood or reactive fluids? What is your position when you have a
patient who is quite stable hemodynamically and has pain and
pleural effusion, what are you doing?
Dr Sundt. We have not tapped those effusions, and in fact, as
far as we could tell from this analysis, the presence of an effusion
didn’t predict behavior either.
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Cho et al Surgery for Acquired Cardiovascular DiseaseDr Tirone E. David (Toronto, Ontario, Canada). Thor, why
don’t you stent them once the diagnosis is made? If 90% to 95%
are located in the proximal descending thoracic aorta, this is a
perfect place to deploy a stent. It doesn’t matter whether the patientThe Journal of ThoracicDr Sundt. I think that deploying a stent is not a zero-risk
proposition. There are all kinds of groin complications that occur
with them, or can occur with them. That is a theoretical issue.
There is a very practical issue as well, which is that we don’t haveA
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